2 completed, 2 recruiting, 1 terminated, 1 withdrawn. 6 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 2, Recruiting 2, Terminated 1, Withdrawn 1 |
Follow Technetium: new trials by email Literature Review of Technetium trials Research Report on Technetium
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones Biospecimen Collection, Bone Scan, Computed Tomography - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma | Phase 1 | Withdrawn | National Cancer Institute (NCI) | 2026-10-01 | 2026-08-28 | |
| Comparative Analysis of Biotinylated, Irradiated and 51-Chromium Radiolabeled Red Blood Cells for Analysis of Recovery and Survival After Autologous Transfusion Biotinylated Red Blood Cells (BioRBC), Irradiated Biotinylated Red Blood Cells (Irradiated BioRBC), 51 Chromium Labeled Red Blood Cells (51Cr RBC) - Healthy Volunteer Red Blood Cell Labeling Study; Not Disease Focused | Phase 1 | Recruiting | Jose Cancelas | 20 | 2026-04-01 | 2026-04-16 |
| Technetium [99mTc]-H7ND in Patients With Gastrointestinal Malignancies and Healthy Volunteers Technetium [99mTc]-H7ND injection - Solid Tumor | Phase 1 | Completed | Jiaxing Pharmadax Genesis Pharmaceutical Technology Co.,Ltd. | 24 | 2024-05-14 | 2025-07-15 |
| A Phase 1 Study of 99mTc-p5+14 in Healthy Volunteers and Patients With AL or ATTR Systemic Amyloidosis 99mTc-p5+14 is an amyloid reactive peptide labeled with technetium-99m., 99mTc-Pyrophosphate - Systemic Amyloidosis | Phase 1 | Recruiting | University of Tennessee Graduate School of Medicine | 31 | 2023-09-18 | 2026-07-24 |
| Lymphoseek as Lymphoid Tissue Targeting Agent in Patients With Cancer of the Endometrium Lymphoseek plus Vital Blue Dye - Endometrial Cancer | Phase 1 | Terminated | University of California, San Diego | 2 | 2015-11-01 | 2018-10-15 |
| Evaluation of the Effect of Fasting and Exercise on Uptake of Tc-99m Sestamibi in Breast Tissue Meal, Exercise, Sestamibi - Molecular Imaging | Phase 1 | Completed | Mayo Clinic | 154 | 2013-09-01 | 2017-04-18 |
Amyloidosis (1) · Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Endometrial Neoplasms (1) · Fasting (1) · Immunoglobulin Light-chain Amyloidosis (1) · Lung Neoplasms (1) · Motor Activity (1) · Prostatic Neoplasms (1)
Jiaxing Pharmadax Genesis Pharmaceutical Technology Co.,Ltd. (1) · Jose Cancelas (1) · Mayo Clinic (1) · National Cancer Institute (NCI) (1) · University of California, San Diego (1) · University of Tennessee Graduate School of Medicine (1)
United States (4) · China (1)
Jonathan S Wall, PhD (1) · Jose A Cancelas-Perez, MD, PhD (1) · Michael K O'Connor, PhD, R-D (1) · Michael McHale, MD, FACS (1) · Zin W Myint (1)
PMID 21045179, PMID 25613340, PMID 30479286
R44CA143716 (1), UM1CA186712 (1)